Analysts Set Aytu BioPharma Inc. (NASDAQ:AYTU) PT at $9.33

Aytu BioPharma Inc. (NASDAQ:AYTU) has been given an average rating of “Hold” by the five analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $9.3333.

A number of research analysts have weighed in on the stock. Ascendiant Capital Markets lifted their price objective on shares of Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Wall Street Zen cut Aytu BioPharma from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, November 24th. Maxim Group reduced their price target on Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, September 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a report on Tuesday, October 14th.

Aytu BioPharma Stock Up 2.0%

Aytu BioPharma stock opened at $2.60 on Friday. The business’s 50-day moving average price is $2.25 and its 200 day moving average price is $2.26. The company has a quick ratio of 1.08, a current ratio of 1.23 and a debt-to-equity ratio of 0.45. The firm has a market cap of $26.49 million, a price-to-earnings ratio of -0.85 and a beta of 0.32. Aytu BioPharma has a 52 week low of $0.95 and a 52 week high of $2.82.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The company had revenue of $13.89 million during the quarter, compared to analysts’ expectations of $17.92 million. Aytu BioPharma had a positive return on equity of 17.86% and a negative net margin of 20.52%.

Institutional Investors Weigh In On Aytu BioPharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP purchased a new position in Aytu BioPharma during the third quarter valued at $58,000. FNY Investment Advisers LLC purchased a new position in Aytu BioPharma in the 2nd quarter valued at about $78,000. Persistent Asset Partners Ltd acquired a new stake in Aytu BioPharma in the 3rd quarter worth about $117,000. Two Sigma Investments LP boosted its holdings in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after buying an additional 33,701 shares during the last quarter. Finally, Kanen Wealth Management LLC purchased a new stake in Aytu BioPharma during the 2nd quarter worth approximately $1,250,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.